Protective effect of bevacizumab on chemotherapy-related acute exacerbation of interstitial lung disease in patients with advanced non-squamous non-small cell lung cancer

Protective effect of bevacizumab on chemotherapy-related acute exacerbation of interstitial lung disease in patients with advanced non-squamous non-small cell lung cancer

Abstract Background Acute exacerbation of interstitial lung disease (AE-ILD) is the most serious complication in lung cancer patients with pre-existing ILD receiving chemotherapy. The role of vascular endothelial growth factor (VEGF) in pathogenesis of AE-ILD is conflicting. The influence of bevaciz...

Full description

Bibliographic Details
Main Authors: Shohei Hamada, Hidenori Ichiyasu, Tokunori Ikeda, Megumi Inaba, Kosuke Kashiwabara, Tomoki Sadamatsu, Nahoko Sato, Kimitaka Akaike, Hiroko Okabayashi, Koichi Saruwatari, Yusuke Tomita, Sho Saeki, Naomi Hirata, Takeshi Yoshinaga, Kazuhiko Fujii
Format: Article
Language:English
Published: BMC 2019-04-01
Series:BMC Pulmonary Medicine
Subjects:
Non-small cell lung cancer
Interstitial lung disease
Acute exacerbation
Bevacizumab
Vascular endothelial growth factor
Online Access:http://link.springer.com/article/10.1186/s12890-019-0838-2

Internet

http://link.springer.com/article/10.1186/s12890-019-0838-2

Similar Items